Stanford Medicine‘s history in cancer immunotherapy dates back to the 1980s – from researching personalized anticancer antibodies to treating pediatric leukemia with T-cells. More recently, Stanford scientists created a host of tools essential to new immunotherapy treatments. They shed light on T-cells, giving scientists a fresh look at the immune system through single-cell analysis and enable the mapping of regulatory DNA. This technology is being used across our research platform, driving PICI research forward. Crystal Mackall, MD | Director Mark Davis, PhD | Co-Director Ansuman Satpathy, MD, PhD | Co-Director All Investigators Related Research Update Where Cancer-killing T-cells Come From Announcement PICI Young Investigator Retreat 2019 Research Update Predicting Childhood Leukemia Relapse Using Machine Learning Announcement, Press Release Dr. Sager Named Recipient of PICI’s Inaugural YIA Award Announcement, Press Release PICI Brings Power of Integrated Network to ASCO 2026 Announcement, Press Release PICI Welcomes Aimee Johnson as Chief Marketing Officer Announcement, Press Release PICI Network Shapes Future of Immunotherapy at AACR 202 Announcement, Press Release PICI and CVC Unite to Accelerate Cancer Vaccines Announcement, Press Release PICI Appoints Bolyn Hubby as Chief of Staff